Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087849612> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3087849612 endingPage "S768" @default.
- W3087849612 startingPage "S768" @default.
- W3087849612 abstract "In patients with MM, brain mets are an indication of poor prognosis, with short OS, PFS and neurological deterioration. Median OS from diagnosis of brain mets is in the range of 17–22 weeks (w), suggesting a crucial need for treatments that can control central nervous system (CNS) progression. Until recently, the management of MM brain mets has included surgical resection, stereotactic radiosurgery, whole-brain radiation therapy, and/or cytotoxic chemotherapy, without a clear change in the natural history of the disease. New drug therapies based on combined BRAF+MEK inhibition for pts BRAF V600 mutant and immunotherapies such as CTLA-4 inhibitors and PD-1 inhibitors, have shown promising results in the setting of MM, leading to median OS of 14-23 months (m). We hypothesize that the early diagnosis of brain mets will improve the symptomatic brain mets free survival (SBMFS) in pts with previously untreated, unresectable or MM by guiding effective treatment options. This is a randomized, open-label, multi-center, phase II study to assess the impact of early detection of asymptomatic brain mets vs standard follow-up on SBMFS in patients with previously untreated, unresectable or MM. A total of 122 pts will be randomized 1:1 to (i) experimental group: serial brain magnetic resonance imaging (MRI); or (ii) control group: standard follow-up. The stratification factors used for randomization are: LDH (normal vs. above upper normal limit); and BRAF V600 (mutated vs. wild-type). Pts in experimental group will undergo brain MRI scans every 16 w or sooner if the patient presents neurological symptoms. Patients in control group will receive neurological examination as per standard of care and CNS imaging will be performed at the time of neurological symptoms/signs. The primary endpoint is SBMFS. The study has 80% power to detect an improvement of 6m in median SBMFS using 80% confidence interval. The follow-up visits in both groups will be every 16 w (+/- 7 d) with a maximum follow-up of 36 m for OS. Recruitment period was estimated in 18 m, with total study duration of 42 m. CA209-7J3/ VHIO19pr001. VHIO; Vall d’Hebron Insitute of Oncology." @default.
- W3087849612 created "2020-10-01" @default.
- W3087849612 creator A5004283107 @default.
- W3087849612 creator A5015909455 @default.
- W3087849612 creator A5021936733 @default.
- W3087849612 creator A5023644419 @default.
- W3087849612 creator A5032580564 @default.
- W3087849612 creator A5032669942 @default.
- W3087849612 creator A5048433520 @default.
- W3087849612 creator A5058998750 @default.
- W3087849612 creator A5076037934 @default.
- W3087849612 creator A5082676408 @default.
- W3087849612 creator A5087015760 @default.
- W3087849612 date "2020-09-01" @default.
- W3087849612 modified "2023-09-27" @default.
- W3087849612 title "1154TiP A randomized, prospective, multicenter study to assess the impact of early detection of asymptomatic brain metastases (mets) vs standard follow-up on symptomatic brain mets free survival (SBMFS) in pts with previously untreated, unresectable or metastatic melanoma (MM)" @default.
- W3087849612 doi "https://doi.org/10.1016/j.annonc.2020.08.1277" @default.
- W3087849612 hasPublicationYear "2020" @default.
- W3087849612 type Work @default.
- W3087849612 sameAs 3087849612 @default.
- W3087849612 citedByCount "0" @default.
- W3087849612 crossrefType "journal-article" @default.
- W3087849612 hasAuthorship W3087849612A5004283107 @default.
- W3087849612 hasAuthorship W3087849612A5015909455 @default.
- W3087849612 hasAuthorship W3087849612A5021936733 @default.
- W3087849612 hasAuthorship W3087849612A5023644419 @default.
- W3087849612 hasAuthorship W3087849612A5032580564 @default.
- W3087849612 hasAuthorship W3087849612A5032669942 @default.
- W3087849612 hasAuthorship W3087849612A5048433520 @default.
- W3087849612 hasAuthorship W3087849612A5058998750 @default.
- W3087849612 hasAuthorship W3087849612A5076037934 @default.
- W3087849612 hasAuthorship W3087849612A5082676408 @default.
- W3087849612 hasAuthorship W3087849612A5087015760 @default.
- W3087849612 hasBestOaLocation W30878496121 @default.
- W3087849612 hasConcept C126322002 @default.
- W3087849612 hasConcept C126838900 @default.
- W3087849612 hasConcept C141071460 @default.
- W3087849612 hasConcept C142724271 @default.
- W3087849612 hasConcept C143409427 @default.
- W3087849612 hasConcept C143998085 @default.
- W3087849612 hasConcept C168563851 @default.
- W3087849612 hasConcept C204243189 @default.
- W3087849612 hasConcept C2776694085 @default.
- W3087849612 hasConcept C2777910003 @default.
- W3087849612 hasConcept C2779130545 @default.
- W3087849612 hasConcept C2780387249 @default.
- W3087849612 hasConcept C2780739268 @default.
- W3087849612 hasConcept C509974204 @default.
- W3087849612 hasConcept C71924100 @default.
- W3087849612 hasConceptScore W3087849612C126322002 @default.
- W3087849612 hasConceptScore W3087849612C126838900 @default.
- W3087849612 hasConceptScore W3087849612C141071460 @default.
- W3087849612 hasConceptScore W3087849612C142724271 @default.
- W3087849612 hasConceptScore W3087849612C143409427 @default.
- W3087849612 hasConceptScore W3087849612C143998085 @default.
- W3087849612 hasConceptScore W3087849612C168563851 @default.
- W3087849612 hasConceptScore W3087849612C204243189 @default.
- W3087849612 hasConceptScore W3087849612C2776694085 @default.
- W3087849612 hasConceptScore W3087849612C2777910003 @default.
- W3087849612 hasConceptScore W3087849612C2779130545 @default.
- W3087849612 hasConceptScore W3087849612C2780387249 @default.
- W3087849612 hasConceptScore W3087849612C2780739268 @default.
- W3087849612 hasConceptScore W3087849612C509974204 @default.
- W3087849612 hasConceptScore W3087849612C71924100 @default.
- W3087849612 hasLocation W30878496121 @default.
- W3087849612 hasOpenAccess W3087849612 @default.
- W3087849612 hasPrimaryLocation W30878496121 @default.
- W3087849612 hasRelatedWork W1505417176 @default.
- W3087849612 hasRelatedWork W2007817983 @default.
- W3087849612 hasRelatedWork W2385706108 @default.
- W3087849612 hasRelatedWork W2404042595 @default.
- W3087849612 hasRelatedWork W2407189953 @default.
- W3087849612 hasRelatedWork W2414040638 @default.
- W3087849612 hasRelatedWork W2468136680 @default.
- W3087849612 hasRelatedWork W2897329785 @default.
- W3087849612 hasRelatedWork W3021135223 @default.
- W3087849612 hasRelatedWork W3029134543 @default.
- W3087849612 hasVolume "31" @default.
- W3087849612 isParatext "false" @default.
- W3087849612 isRetracted "false" @default.
- W3087849612 magId "3087849612" @default.
- W3087849612 workType "article" @default.